ED
PSNL icon

Exane Derivatives’s Personalis PSNL Stock Holding History

Exane Derivatives’s Portfolio PSNL Stock Details PSNL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,134
Closed -$79.5K – 943
2021
Q3 		$79.5K Buy
4,134
+1,613
+64% +$33.7K 0.02% 562
2021
Q2 		$56.1K Buy
+2,521
New +$57.7K 0.01% 637

Other funds holding PSNL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Exane Derivatives's PSNL Position: Q4 2021 in Review

Exane Derivatives sold out of Personalis (PSNL) in Q4 2021, closing a stake of 4,134 shares — an estimated $79.5K sold.

Exane Derivatives first reported a position in PSNL in Q2 2021 and held it in 2 quarters. The position peaked at $79.5K in Q3 2021. 108 funds tracked by Wall St. Rank hold PSNL as of Q4 2021.

  • Exane Derivatives reported no remaining Personalis position as of Q4 2021 after selling out during the quarter.
  • Exane Derivatives sold 4,134 Personalis shares in Q4 2021, an estimated $79.5K.
  • Exane Derivatives first reported a position in Personalis in Q2 2021 and held it in 2 quarters.
  • Exane Derivatives's Personalis position peaked at $79.5K in Q3 2021.
  • 108 funds tracked by Wall St. Rank held Personalis as of Q4 2021.

Based on Exane Derivatives's 13F filing for Q4 2021, filed 28 Jan 2022.